AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No: 198403368H)
(Incorporated in the Republic of Singapore)

ENTER INTO A BINDING MEMORANDUM OF UNDERSTANDING FOR STRATEGIC COOPERATION ON HUMANOID ELDERLY CARE ROBOTS

The Board of Directors (the "**Board**" or "**Directors**") of AJJ Medtech Holdings Limited (the "**Company**" or "**AJJ**"**,** and together with its subsidiaries, the "**Group**") is pleased to announce that on 12 November 2025, it has entered into a legally binding Memorandum of Understanding **("MOU")** with Autagco Ltd ("**Autagco**"), to jointly develop, deploy, and commercialise **Humanoid Elderly Care Robots** within Autagco's senior assisted living facilities in Singapore.

This strategic partnership leverages AJJ's expertise in humanoid robotics, artificial intelligence, and digital health solutions, and Autagco's operational experience in elderly care. The collaboration aims to transform Autagco's assisted living facilities into AI-powered intelligent care environments, providing a model for scalable, high-quality eldercare services.

Autagco Ltd (SGX: 1D3) is listed on the Catalist Board of the Singapore Exchange. Autagco's primary business is in premium senior assisted living and wellness. Operated through its wholly-owned subsidiary, Communa Gold Pte Ltd, the Company manages and develops assisted living communities that integrate hospitality services, personalized wellness programs, and technology-driven care services for active seniors who seek independent living with support and community interaction.

By combining AJJ's advanced humanoid robotics capabilities with Autagco's operational footprint in Singapore's assisted living market, this collaboration aims to establish a scalable model for technology-enabled eldercare services and supports future expansion opportunities in the region.

This collaboration represents the launch of the World's First Multifunctional Humanoid Elderly Care Robot. This follows the Company's announcement dated 12 October 2025, to develop and operate the World's First Multifunctional Humanoid Robot for elderly care.

1. Scope of Cooperation

Procurement and Deployment:
At the initial stage, Autagco will acquire six (6) units of AJJ-HT-X1 Humanoid Elderly Care Robots for deployment across its assisted living facilities operated by its wholly-owned subsidiary, Communa Gold

Pte. Ltd., subject to the AJJ & Autagco entering into a mutually agreed supply agreement. All pilot testing, operation, and service deployment will be confined to Autagco's group facilities.

Clinical Trials and Application:
Clinical trials and operational application of the robots will be conducted within Autagco's group facilities to validate safety, effectiveness, and functional capabilities such as companionship, rehabilitation assistance, health monitoring, and cognitive interaction.

All trial data will be anonymised and handled in compliance with Singapore's Personal Data Protection Act (“**PDPA**”).

2. **Key Responsibilities**

AJJ: Responsible for obtaining regulatory approvals, handling importation, Health Sciences Authority (“**HSA**") registration, provision of robot hardware and technology, data collection and analysis, cybersecurity, and liaison with clinical experts.

Autagco: Provides its assisted living facilities for clinical trials and deployment, reports to the Ministry of Health (“**MOH**”), facilitates staff training and operational integration, and supports commercialisation within its facilities.

Joint Responsibilities: Both AJJ and Autagco will share necessary resources, liaise with relevant local and international medical and elderly care institutions, and ensure all activities comply with applicable laws and regulations.

3. Legal and Regulatory Compliance

Both AJJ and Autagco commit to strict compliance with Singapore laws, including SGX Listing Rules.

AJJ shall progressively comply with the HSA for medical devices regulatory requirements in line with the robots’ functional development, while Autagco shall follow the regulatory requirements setforth by MOM under the Workplace Safety and Health Act and the Artificial Intelligence in Healthcare Guidelines setforth by MOH.

All data handling and AI algorithm deployment shall comply with PDPA and GovTech/IMDA AI Verify standards.

4. Strategic Significance

The cooperation aims to:

- Integrate AI-powered humanoid robotics into real-world eldercare scenarios within Autagco's facilities.
- Accelerate product validation, regulatory compliance, and operational readiness.
- Establish a replicable model for commercial deployment within Autagco's network.
- Enhance brand recognition and social impact in the intelligent elderly care sector.

5. Validity

The MOU is valid for 36 months (from 12 Nov 2025) and may be renewed upon mutual agreement.

6. Interests of the Directors and Controlling Shareholders

The Board confirms that to its best knowledge and belief, save for their respective shareholding interests in the Company, none of the Directors or controlling shareholders has any interest, direct or indirect, in the MOU.

7. Cautionary Statement

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

While the Board believes that this strategic collaboration marks a significant milestone in the commercialisation of humanoid elderly care robotics and presents a substantial long-term growth opportunity for the Group, the successful implementation of the initiative remains subject to factors such as regulatory clearance, deployment readiness, and operational scaling.

As AJJ progresses toward these key development milestones, including the initial pilot testing, obtaining HSA approval for clinical trials, and subsequent execution towards full commercialisation, any material advancements are expected to meaningfully enhance the Group's positioning within Singapore's rapidly expanding intelligent eldercare market. The Company will make further announcements as and when there are material developments in accordance with the SGX-ST Listing Rules.

8. Forward-Looking Statements

This announcement may contain forward-looking statements, including expectations regarding commercialisation, regulatory approvals, and market adoption.

Actual results may differ due to market conditions, regulatory changes, and operational risks.

BY ORDER OF THE BOARD

Zhao Xin
Chief Executive Officer and Executive Director
13 November 2025

This document has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02 SBF Center, Singapore 068914.